Who Qualifies for a GLP-1 Medication?
What the FDA labels for Wegovy, Zepbound and Foundayo say about who the medicines are for, who should not take them, and where insurance rules differ.
What the labels say
All three weight-management labels use the same structure: the medicine is used with a reduced-calorie diet and more physical activity in adults with obesity, or in adults with overweight who have at least one weight-related comorbid condition.
- Wegovy (injection and tablets): weight reduction and long-term maintenance, plus lowering the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. The injection also covers patients 12 and older with obesity and a liver indication (MASH with moderate to advanced fibrosis).
- Zepbound: weight reduction and maintenance in adults with obesity or with overweight and a weight-related condition, and moderate to severe obstructive sleep apnea in adults with obesity.
- Foundayo: weight reduction and maintenance in adults with obesity, or with overweight and at least one weight-related condition.
Where BMI comes in
The current labels do not write a BMI cutoff into the indication. The trials that supported them did. In the Wegovy label, the 68-week Study 2 enrolled adults with a BMI of 30 or more, or 27 to 29.9 with at least one weight-related condition. That is why you will often see 30, or 27 with a condition, quoted as the working threshold. It is a trial description, not a rule your prescriber or plan must follow.
Who should not take them
- Anyone with a personal or family history of medullary thyroid carcinoma, or with MEN 2.
- Anyone with known serious hypersensitivity to semaglutide or tirzepatide or their ingredients (Wegovy and Zepbound labels).
- People who are pregnant. The Wegovy label says it may cause fetal harm and to stop when pregnancy is recognized, and advises stopping at least 2 months before a planned pregnancy.
- Use together with another GLP-1 receptor agonist is not recommended.
The labels also list warnings for pancreatitis, gallbladder disease, kidney injury from dehydration and others. See GLP-1 side effects.
Coverage is a separate question
Meeting the label description does not mean a plan will cover the drug. Plans set their own criteria and often require prior authorization. Read whether insurance covers Zepbound and Wegovy, and if you are denied, how to appeal. Paying yourself is covered in GLP-1 cost without insurance.
Educational information, not medical advice. Only a licensed prescriber can decide whether a GLP-1 medicine is right for you.
Frequently asked questions
What BMI do you need for a GLP-1 weight loss drug?
The current Wegovy and Zepbound labels describe adults with obesity, or adults with overweight who have at least one weight-related condition, and do not set a BMI number in the indication. In the Wegovy label, the main trial enrolled adults with a BMI of 30 or more, or 27 to 29.9 with at least one weight-related condition such as dyslipidemia or hypertension. A prescriber decides who is a fit.
What counts as a weight-related condition?
The Wegovy label trial examples are treated or untreated dyslipidemia or hypertension. The Zepbound label also covers moderate to severe obstructive sleep apnea in adults with obesity. Your prescriber and your plan define the list that applies to you.
Can I get Wegovy or Zepbound without diabetes?
Yes. Wegovy and Zepbound are approved for weight management and do not require diabetes. Ozempic and Mounjaro are the versions labeled for type 2 diabetes.
Who should not take a GLP-1 medicine?
The labels for Wegovy, Zepbound and Foundayo say not to use them with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. The Wegovy and Zepbound labels also list known serious hypersensitivity to the medicine as a contraindication. The labels also warn about pancreatitis, gallbladder disease and other risks, and say pregnancy may cause fetal harm. Tell your prescriber your full history.
Can teenagers take them?
The Wegovy injection label includes patients aged 12 and older with obesity. The Wegovy tablet, Zepbound and Foundayo indications are for adults. Anyone under 18 needs a clinician experienced with pediatric obesity care.
Does meeting the label criteria mean insurance will pay?
No. Plans set their own coverage rules and often require prior authorization. See our insurance guides, and see the self-pay price guide if coverage is denied.